Cargando…

Unpredicted Severe Toxicity after 5-Fluorouracil Treatment due to Dihydropyrimidine Dehydrogenase Deficiency

Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU). Thus, patients with a DPD deficiency are at risk of developing severe 5-FU-associated toxicity. A 37-year-old female with gastric cancer underwent a curative operation, followed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baek, Jin Ho, Kim, Jong Gwang, Kim, Shi Nae, Kim, Dong Hwan, Sohn, Sang Kyun, Hong, Young Jun, Lee, Kyu Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2006
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891063/ https://www.ncbi.nlm.nih.gov/pubmed/16646564 http://dx.doi.org/10.3904/kjim.2006.21.1.43

Ejemplares similares

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
por: Milano, G, et al.
Publicado: (1999)

Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity
por: Fidai, Shiraz S., et al.
Publicado: (2018)

Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy
por: Diasio, Robert B., et al.
Publicado: (2022)

Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study
por: Detailleur, Stephanie, et al.
Publicado: (2021)

Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays
por: De Luca, Ottavia, et al.
Publicado: (2022)

Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
por: Vogel, Wendy H., et al.
Publicado: (2020)

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
por: de With, M., et al.
Publicado: (2023)

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase
por: Falvella, Felicia Stefania, et al.
Publicado: (2015)

High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity
por: Borràs, Emma, et al.
Publicado: (2013)

Abnormal Dihydropyrimidine Dehydrogenase Activity as an Indicator of Potential 5-Fluorouracil Linked Cardiotoxicity in Colorectal Cancer Patients: Are Toxic Events Inevitable?
por: Chakwop Ngassa, Hyginus, et al.
Publicado: (2021)

Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase
por: Kang, Jihyun, et al.
Publicado: (2021)

Dihydropyrimidine Dehydrogenase and Messenger RNA Levels in Gastric Cancer: Possible Predictor for Sensitivity to 5‐Fluorouracil
por: Ishikawa, Yoichiro, et al.
Publicado: (2000)

Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report
por: Palmirotta, Raffaele, et al.
Publicado: (2019)

Evaluation of Clinical Value of Single Nucleotide Polymorphisms of Dihydropyrimidine Dehydrogenase Gene to Predict 5-Fluorouracil Toxicity in 60 Colorectal Cancer Patients in China
por: Zhang, Xin, et al.
Publicado: (2013)

An incidental case of dihydropyrimidine dehydrogenase deficiency: One case, multiple challenges
por: Al Khallaf, Hamoud H., et al.
Publicado: (2013)

Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review
por: Hagiwara, Yuya, et al.
Publicado: (2022)

Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma
por: Akhter, Khaleda, et al.
Publicado: (2019)

Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene
por: García-González, Xandra, et al.
Publicado: (2018)

Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity
por: van Kuilenburg, André B. P., et al.
Publicado: (2010)

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.
por: McLeod, H. L., et al.
Publicado: (1998)

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.
por: Ridge, S. A., et al.
Publicado: (1998)

Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door
por: Donadio, Mauro Daniel Spina, et al.
Publicado: (2022)

Screening of Dihydropyrimidine Dehydrogenase Genetic Variants by Direct Sequencing in Different Ethnic Groups
por: Shin, Joong-Gon, et al.
Publicado: (2013)

Germline Mutation of Dihydropyrimidine Dehydrogenese Gene among a Japanese Population in Relation to Toxicity to 5‐Fluorouracil
por: Yamaguchi, Kensei, et al.
Publicado: (2001)

Regulation of Dihydropyrimidine Dehydrogenase and Pyrimidine Nucleoside Phosphorylase Activities by Growth Factors and Subsequent Effects on 5‐Fluorouracil Sensitivity in Tumor Cells
por: Ueda, Masatsugu, et al.
Publicado: (2000)

Outpatient-basis Chemotherapy of Oxaliplatin, 5-fluorouracil, and Leucovorin as First-line Treatment for Patients with Metastatic or Recurrent Colorectal Cancer
por: Moon, Joon Ho, et al.
Publicado: (2007)

Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
por: Del Re, Marzia, et al.
Publicado: (2010)

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer
por: Horiguchi, J, et al.
Publicado: (2002)

A ferredoxin-dependent dihydropyrimidine dehydrogenase in Clostridium chromiireducens
por: Wang, Feifei, et al.
Publicado: (2020)

Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping
por: Royer, B., et al.
Publicado: (2023)

Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine
por: Tsukahara, Shigehiro, et al.
Publicado: (2022)

Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency
por: Maillard, Maud, et al.
Publicado: (2022)

Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil
por: Yamada, Y, et al.
Publicado: (2003)

Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients
por: Gross, Eva, et al.
Publicado: (2008)

Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin's Lymphoma
por: Kim, Jong Gwang, et al.
Publicado: (2004)

A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity
por: Nagaharu, Keiki, et al.
Publicado: (2016)

Detection of complete Dihydropyrimidine Dehydrogenase deficiency in a Tunisian family using a simple phenotypic test
por: Mani, Arij, et al.
Publicado: (2013)

Cytomegalovirus enterocolitis in a patient with dihydropyrimidine dehydrogenase deficiency after capecitabine treatment: A case report
por: Inoue, Fumiya, et al.
Publicado: (2019)

Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients
por: Del Re, Marzia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_96dnic11j0p46mqgt2va0biq5f